13.85
전일 마감가:
$14.07
열려 있는:
$14.07
하루 거래량:
75,116
Relative Volume:
0.60
시가총액:
$120.94M
수익:
$123.24M
순이익/손실:
$136.00K
주가수익비율:
-692.50
EPS:
-0.02
순현금흐름:
$-148.99M
1주 성능:
-6.73%
1개월 성능:
+87.16%
6개월 성능:
-5.27%
1년 성능:
-43.47%
Seres Therapeutics Inc Stock (MCRB) Company Profile
명칭
Seres Therapeutics Inc
전화
617 945 9626
주소
200 SIDNEY STREET, CAMBRIDGE, MA
MCRB을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
MCRB
Seres Therapeutics Inc
|
13.85 | 129.68M | 123.24M | 136.00K | -148.99M | -0.02 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-05-08 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
2024-10-24 | 다운그레이드 | JP Morgan | Neutral → Underweight |
2023-06-26 | 재개 | Oppenheimer | Outperform |
2023-04-21 | 개시 | JP Morgan | Neutral |
2021-07-23 | 다운그레이드 | Goldman | Neutral → Sell |
2021-05-18 | 재개 | Goldman | Neutral |
2021-03-05 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
2020-09-18 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
2020-08-18 | 개시 | Piper Sandler | Overweight |
2020-08-11 | 재확인 | H.C. Wainwright | Buy |
2020-08-11 | 업그레이드 | Jefferies | Hold → Buy |
2019-04-30 | 개시 | Jefferies | Hold |
2018-10-22 | 개시 | Chardan Capital Markets | Buy |
2017-10-13 | 개시 | Oppenheimer | Outperform |
2017-08-04 | 재확인 | H.C. Wainwright | Buy |
2017-02-01 | 재확인 | FBR & Co. | Outperform |
2016-08-12 | 재확인 | FBR Capital | Outperform |
2016-08-01 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
2016-08-01 | 재확인 | H.C. Wainwright | Buy |
2016-07-29 | 재개 | H.C. Wainwright | Buy |
2016-03-30 | 개시 | FBR Capital | Outperform |
2016-03-03 | 개시 | Guggenheim | Buy |
2016-01-25 | 개시 | H.C. Wainwright | Buy |
2015-10-22 | 업그레이드 | BofA/Merrill | Neutral → Buy |
2015-07-22 | 개시 | Canaccord Genuity | Buy |
2015-07-21 | 개시 | Goldman | Neutral |
2015-07-21 | 개시 | Leerink Partners | Outperform |
모두보기
Seres Therapeutics Inc 주식(MCRB)의 최신 뉴스
Seres Therapeutics, Inc.'s (NASDAQ:MCRB) top owners are individual investors with 51% stake, while 23% is held by institutions - Yahoo Finance
Is Seres Therapeutics Inc. a good long term investmentOutstanding investment returns - PrintWeekIndia
What drives Seres Therapeutics Inc. stock priceBreakthrough capital growth - jammulinksnews.com
Seres Therapeutics Inc. Stock Analysis and ForecastTremendous return on equity - Autocar Professional
individual investors who own 52% along with institutions invested in Seres Therapeutics, Inc. (NASDAQ:MCRB) saw increase in their holdings value last week - simplywall.st
What analysts say about Seres Therapeutics Inc. stockDynamic investment opportunities - jammulinksnews.com
what makes seres therapeutics inc. stock price move sharplyChart Breakout Alert - Newser
How high can Seres Therapeutics Inc. stock price go in 2025Protected Capital Trading Plan - Newser
What makes Seres Therapeutics Inc. stock price move sharplyFree Trading Group - Newser
How Seres Therapeutics Inc. stock performs during market volatilityWatchlist Winner Update - Newser
Why Seres Therapeutics Inc. stock attracts strong analyst attentionFree Smart Money Group - Newser
Seres Therapeutics Soars 21%—What’s Fueling the Biotech Breakout? - AInvest
5 Best Microbiome Companies (July 2025) - Securities.io
Seres Therapeutics, Inc.(NasdaqGS: MCRB) added to Russell 3000E Index - MarketScreener
Seres Therapeutics, Inc.(NasdaqGS: MCRB) added to Russell Microcap Growth Index - MarketScreener
Seres Therapeutics May 2025 slides: SER-155 shows 77% infection reduction in transplant patients - Investing.com
FMR LLC Reduces Stake in Seres Therapeutics Inc: A Strategic Rea - GuruFocus
Denodo University Challenge Now Open: Data and AI for Real-World Impact - GlobeNewswire Inc.
Seres Therapeutics, Inc. (NASDAQ:MCRB) Given Consensus Recommendation of “Reduce” by Brokerages - Defense World
Seres Therapeutics reports promising biomarker data By Investing.com - Investing.com South Africa
Seres Therapeutics (MCRB) to Present New Biomarker Data at ASCO 2025 | MCRB Stock News - GuruFocus
Seres Therapeutics reports promising biomarker data - Investing.com
Seres Therapeutics to Present New Biomarker Data from SER-155 Phase 1b Study at 2025 ASCO Annual Meeting - Nasdaq
Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting - The Manila Times
Breakthrough: Seres Therapy Cuts Deadly Infection Risk by 77% in Cancer Transplant Patients, ASCO Data Shows - Stock Titan
Seres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Seres Therapeutics (NASDAQ:MCRB) Shares Pass Below Two Hundred Day Moving Average – Here’s Why - Defense World
Wall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to Trade - NewsBreak: Local News & Alerts
Human Microbiome Market Forecast: Growth Trends, Key Players & - openPR.com
Seres Therapeutics’ (MCRB) “Neutral” Rating Reiterated at Chardan Capital - Defense World
StockNews.com Upgrades Seres Therapeutics (NASDAQ:MCRB) to Hold - Defense World
Seres Therapeutics Shares Fall After Downgrade From Chardan - marketscreener.com
Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2025 Earnings Call Transcript - Insider Monkey
This Coty Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday - Benzinga
Chardan Downgrades Seres Therapeutics to Neutral From Buy, Adjusts Price Target to $6 From $25 - marketscreener.com
MCRB: Seres Therapeutics' Price Target Raised by Chardan Capital | MCRB Stock News - GuruFocus
Chardan cuts Seres Therapeutics stock rating to neutral - Investing.com
Seres Therapeutics: Q1 Earnings Snapshot - Norwalk Hour
Seres Therapeutics Reports Positive Q1 2025 Results - TipRanks
Seres Therapeutics’ Positive Earnings Call: Progress and Challenges - TipRanks
Transcript : Seres Therapeutics, Inc., Q1 2025 Earnings Call, May 07, 2025 - marketscreener.com
Seres Therapeutics Inc (MCRB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):